GB2170499A - Pesticidal and anthelmintic milbemycins - Google Patents
Pesticidal and anthelmintic milbemycins Download PDFInfo
- Publication number
- GB2170499A GB2170499A GB08600494A GB8600494A GB2170499A GB 2170499 A GB2170499 A GB 2170499A GB 08600494 A GB08600494 A GB 08600494A GB 8600494 A GB8600494 A GB 8600494A GB 2170499 A GB2170499 A GB 2170499A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compound
- formula
- methyl
- compounds
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Agronomy & Crop Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compounds of formula (I): <IMAGE> wherein R<1> is hydroxy, R<2> is hydrogen or methyl, R<3> is methyl, and R<4> is 2,4-dimethylpentanoyl or 2,4-dimethylpent-2-enoyl, have pesticidal and anthelmintic activity.
Description
SPECIFICATION
Macrocyclic lactones
This invention relates to novel compounds and to their use as pesticides and anthelmintics. The milbemycins are a group of macrocyclic lactones obtained from the fermentation of microorganisms for example as described in US Patent 3,984,564.
We bare no.w discovered that fermentation of certain organisms under specified conditions gives rise to a number of milbemycin species not previously described.
The present invention provides a compound of formula (1)
wherein
(a) Rz is hydroxy, R2 is hydrogen or methyl, R3 is methyl, and R4 is 2,4-dimethylpentanoyl or 2,4-dimethylpent-2-anoyl; or
(b) Rr is hydroxy, R2 is hydrogen or methyl, R3 is methyl, and R4 is 2-methylbutanoyl; or
(c) R1 is hydroxy, R2 is hydrogen, R3 is ethyl, and R4 is 2,4-dimethylpentanoyl; or
(d) R1 and R4 are both hydrogen, and R2 and R3 are both methyl.
Particular compounds according to the invention are those set out in Table 1 below wherein the meanings of R1, R2, R3 and R4 in Formula I are given for each compound.
Compound Ra R2 R3 R4 No. O CH2 III 1 OH CH2 CH3 C-CH-CH2-CH3 O CH3 CH3 II l I 2 OH CH3 CH3 -C-C=CH-CH-CH3 3 H CH3 CH3 H O CH3 CH2 II l I 4 OH H CH3 -C-C=CH-CH-CH3 O CH3 CH3 II l I 5 OH H CH3 -C-CH-CH2-CH2-CH3 O CH3 OH3 II l I 6 OH CH3 CH3 -C-CH-CH2-CH-CH3 O CH3 CH3 III I 7 OH H CH2CH3 -C-CH-CH2-CH-CH3 O CH3 8 OH H CH3 II I -C-CH-CH2-CH3
The compound of formula I are belived to be isolated as singel isomers having a particular stereochemistry as represented by formula (IA) :
This was determined by analogy with the absolute stereochemistry for known milbemycins given for example in J. Antibiotics 33 (10), 1121. However, the invention herein relates to the compounds actually obtained by fermenting the microorganism and as defined hereinafter by various physical and chemical parameters and is not intended to be limited to the particular stereochemical isomers shown in formula (IA).
The compounds of formula (I) are prepared by fermentation techniques. Further according to the present invention there is provided a process for preparing a compound of formula (I) which process comprises cultivating a strain of Streptomyces and isolating the compound of formula (I) from the fermentation mixture.
A suitable strain of streptomyces is the B41-146 strain (fully described in US Patent 3,984,564) of a
Streptomyces species which has been deposited at the Northern Research Laboratory, US Department of
Agriculture, Peoria, Illinois, USA under deposit number NRRL 5739, and at the National Collection of Industrial and Marine Bacteria, 135 Abbey Road, Aberdeen, Scotland under deposit number NCIB 11876, or a mutant thereof.
The fermentation procedure and isolation techniques are set out below in Example 1.
The compounds are useful as pesticides, particularly as insecticides, acaricides and nematicides, and as anthelmintics.
They are suitably administered to the pest or its environment in the form of a composition comprising the compound of formula (I) and an appropriate carrier or diluent. Such compositions form a further aspect of the invention.
The compositions are suitably formulated in a conventional manner depending upon the intended use.
Thus for use as insecticides, acaricides or nematocides, they can be applied in any of the forms conveniently employed in agriculture. Thus in a further aspect, the invention provides an insecticidal composition comprising a compound of formula (I) as hereinbefore defined or a salt thereof in combination with an agriculturally acceptable carrier.
Depending on the intended use, one or more compounds of formula (I) are either dissolved or dispersed in a suitable liquid vehicle or admixed with or adsorbed on a suitable solid vehicle and the resulting composition -is made available in any of such forms as emulsifiable concentrate, oil, wetter powder, dusts, granules, tablets, aerosol mist, ointment, etc. There may also be added to these preparations such additives as emulsifers, suspending agents, extenders, penetrants, wetting agents, thickners or stabilizers, as necessary. These preparations can be produced by the known methods.
The proportion of the compound of formula (I) in such an insecticidai/acaricidal preparationdepends - on the intended use and application.
For use as an anthelmintic, the compound of formula (I) is suitably combined with a pharmaceutically acceptable carrier. The composition thus formed can be suitable for oral or parenteral administration as is known in the art. The dosage employed will depend upon the animal being treated and the severity of the conditions.
The following examples illustrate the invention.
Example 1 The organism used was a Streptomyces strain identified as NCIB 11876 which has been deposited with the National Collection of Industrial and Marine Bacteria, 135 Abbey Road, Aberdeen AB9 BDG, Scotland.
An innoculum was grown on an Oatmeal Agar slope, streaked 20 days earlier at 28"C. 10 ml of a
Starter seed medium (Y. Takiguchi eta/Journal of Antibiotics, October 1980, p1120) was used to dislodge spores and mycelium from those slopes and the resulting suspension was pipetted out into 2 fresh 250 ml Erlenmeyer flasks containing 25 ml of starter seed medium. These were incubated on an orbital shaker at 200 rpm at 28"C for 2 days before 20 aliquots of 5 ml were used to innoculate 20 250 ml flasks each containing 25 ml of seed medium. After 2 days shaking as before, these were used to innoculate a 14 1 capacity "Microferm" (New Brunswick Scientific (UK) Ltd) fermentation vessel containing 9 1 of fermentation medium (Y.Takiguchi eta/Journal of Antibiotics, October 1980, p1120). Aeration was at 8 1 of air/minute supplemented by stirring at 400 rpm at 28"C with polypropylene glycol (25 ml) acting as an inert antifoaming agent. The grow was harvested after 7 days by centrifugation at 3000 rpm for 10 minutes (Damon/lEC PR-6000) to separate the plentiful actinomycete pellets. At harvest, the whole broth was a deep yellow colour.
The centrifuged mycelium was taken and allowed to stand overnight at room temperature with 2 1 of methanol. After filtration, the solid residue was re-extracted twice with methanol (1 litre) and all the aqueous methanol extracts were combined. The resulting solution (approx 5 1) was concentrated in vacuo to approximately 1.5 1 before partitioning with hexane (2 portions of 1.5 1). The hexane phases were concentrated to dryness and redissolved in methanol (400 ml) which was stored overnight at -20 C. The resulting precipitate was removed by filtration, the filtrate was concentrated to yield a brown oil (12.22g).
The brown oil (10g) was applied to a column of Kieselgei 60 (E. Merck, Darmstadt) (25 cm by 3 cm) which was successively eluted with hexane: acetone 95:5 (1 litre), 90:10 (1.3 litre) and 80:20 (1 litre) followed by acetone (0.5 litre) and finally methanol (0.5 litre) to give 18 fractions.
Fraction 12 (400 mg) was chromatographed on silica-gel 60-F254 preparative plates (0.25 mm) developed in chloroform:ethyl acetate 3:1 to give bands discernible by their quenching of gel fluorescence under short wave UV radiation. These areas of silica were removed from the plates and eluted with methanol to yield five fractions; 12A (38 mg, Rf=0.53), 12B (16 mg, Rf=0.47), 12C (31 mg, Rf=0.38), 12D (73 mg, Rf=0.29) and 12E (72 mg, Rf-0.26). HPLC showed fractions 12A to 12C contained compounds of interest and so portions of each were further purified by semi-preparative reverse phase HPLC (using a HICHROM S50DS-2 column [150 mm by 8 mm] eluted with 2.5 milmin of 85% methanol water using UV detection at 246 nm) to provide pure samples of milbemycins designated as compounds 1, 2, 3 and 6.
These were each analysed by electron impact and chemical ionisation (the reagent gas was ammonia) mass spectrometry on a Finnigan-Mat 8200 mass spectrometer (Table B) and UV (in methanol using a
Pye Unicam instrument) (Table A); these techniques revealed the compounds to be unlike any previously reported.
The accurate masses of the molecular ions of compounds 1-3 and 6 were determined by high resolution mass spectrometry (Finnigan-Mat 8200 peak matching in comparison with perfluorokerosene [PFK] the results are shown in Table C along with the corresponding empirical formulae. The compounds were also investigated by 400 MHz NMR (Jeol GX400), the chemical shift data are shown in Tables D and E.
From the combination of this information it was possible to assign the structures for compounds 1 and 2.
There was insufficient material for confirmation of the structure of compound 3 but the mass spectral evidence indicates it to have the structure shown in Table I.
Compound 6 was identical by mass spectrometry to the previously reported alpha 6 (Takiguchi, Mishima, Okuda and Terao; Journal of Antibiotics, 1980, 33 (10), 1120 1127). However, careful interpretation of the 400 MHz NMR proton spectrum showed the presence of 6 methyl doublets (at delta 1.01 [cl2-Me], 0.83 [C24-Me], 1.22 [C26-Me], 1.17 [C21-Me], 0.88 and 0.91 [C-5 -Methyls] where only four doublets and one triplet would be expected for alpha 6, COSY 2D-NMR allowed the full assignment of the spectrum shown in Tables D and E; corresponding to the structure shown in Table
Fraction 14 (1017 mg) from the original silica column was further purified on a LOBAR normal phase silica column (E MERCK) eluted with hexane:ethanol 96:4 and 94:6 using UV detection at 246 nm. to yield 80 fractions. These were analysed by TLC (Silica gel 60-F254, eluted with hexane-acetone 65:35, compounds were visualised by their queching of gel fluorescence under UV light at 254 nm and by the blackish coloured spots on a yellow background generated with "phosphomolybdate spray reagent".The fractions were also examined by anaytical HPLC (SpectraPhysics SP8100 with HICHROM S50DS-2 [250 by 4.9 mm] at 40"C eluted with 1 ml/min of a programmed solvent gradient ranging from.methanol:water 83:17 to 100% methanol over 35 minutes (15 mins isocratic followed by a linear gradient). Under these conditions, the compounds have the following retention times 1=10 min, 2=12.6 min, 3=7.8 min, 4=10.0 min, 5=11.9 min, 6=15.6 min and 7=15.2 min). Appropriate fractions (181 mg) were combined prior to preparative TLC on 4 silica gel 60-F254 preparative plates (2.5 mm). The developing solvent was chloroform:acetone 3:1.Fluoroescence quenching bands at Rf=0.23, 0.46, 0.65 and 0.96 were removed and eluted with ethyl acetate (2 by 50 mls) to give four fractions. One of these was shown to contain significant quantities of compounds of interest which were cleaned up by semi-preparative HPLC to yield three pure compounds designated 4, 5 and 7. Analysis as before gave the mass spectral, UV and NMR data shown in tables B, A, D and E and allowed the assignment of structures given in Table I. Again, with compounds 5 and 7, mass spectral evidence suggested that the materials were the previously reported alphas 5 and 7 but the NMR confirmed the presence of the terminal iso-propyl group on the C-23 ester chain. Decoupling experiments on the protons coupling to some of the methyl groups of compound 5 confirmed the assignments.No trace of the straight chain compounds could be found.
A repeat grow of this microorganism resulted in the isolation of larger quantities of novel compounds 1, 2, 4 and 5. In addition, a further novel compound designated 8 has been isolated and identified by nmr, UV and mass spectral data.
TABLE A
Compound UV absorbance maxima (nm) - methanol No. solution
1 237 (sh) 244 251 (sh)
2 236 244 252 (sh)
3 237 244 252 (sh)
4 238 (sh) 246 254 (sh)
5 239 (sh) 246 253 (sh)
6 238 (sh) 246 253 (sh)
7 238 (sh) 246 253 (sh)
8 237 (sh) 244 253 (sh)
TABLE B
Compound Mass Spectral Data - fragment ions (M+)
No.
1 658 640 458 414 396 264 246
195 167 151 125
2 684 666 458 414 396 264 246
195 167 151 125 111
3 558 540 522 398 380 248 229
197 179 169 161 151 125
4 670 652 560 524 444 427 414
396 278 264 195 167 151 111
5 672 264 562 524 444 427 414
396 278 264 195 167 151 85
6 686 668 458 414 396 264 246
195 167 151 125 85
7 686 668 576 444 428 410 293
278 248 209 181 151 85
8 644 626 608 534 444 427 414
396 195 167 151
TABLE C
CompoundMass Spectral Data: Calculated Molecular
No. Accurate Mass (M') Formula
1 658,371812 C37H54O10
2 684,387596 C39H56O10
3 558.319057 C32H4nO8 6 686.4042 C3nH5nO1o Nuclear Magnetic Resonance data are given in the following two tables.The location of the relevant protons is given according to the numbering of the carbon atoms in them ilbemycin skeleton as follows
TABLE D
Location of Nmr Data (CDCl3. Standard - tetramethylsilane) #. for Compound No.
Protons for Compound No.
(C-number) 1 2 3 4 5 6 7 8 2 3.32 3.32 3.28 3.28 3.32 3.28 3.28 3.26 3 5.39 5.39 5.41 5.40 5.38 5.40 5.39 4 (CH3) 1.82 1.82 1.88 1.87 5(H1CH3) 3.97,3.52 3.98,3.52 4.29,- 4.29,2.32 3.97,3.52 4.29,2.34 4.28,2.32 6 4.03 4.03 3.96 3.96 4.04 3.96 3.95 7 (OH) 4.00 4.02 4.68 3.94 4.00 3.94 3.93 8 4.66 4.65 5.78 4.68 4.66 4.68 4.66 9 5.77 5.77 5.74 5.79 5.76 5.80 5.76 10 5.74 5.74 5.74 5.75 5.74 5.75 5.74 11 5.35 5.34 5.37 5.35 5.38 5.36 5.35 12 (H.CH3) 2.43,1.00 2.43,- 2.43,1.01 2.42,1.00*n 2.43-1.01 2.42,0.99 13 (a,e) 1.86,2.21 1.85,2.21 14 (CH3) 1.54 1.54 1.53 1.52 15 4.97 4.97 4.97 4.96 4.96 4.94 4.96 16 2.23 2.22 2.22 2.22 2.22 TABLE E
Location of Nmr Data (CDCI3, Standard - tetramethylsilane) #, for Compound No.
Protons for Compound No.
(C-number) 1 2 3 4 5 6 7 8 17 3.58 3.60 3.60 3.60 3.59 18 (a,e) 0.92,1.82 0.90,1.82 0.90,1.82 19 5.32 5.33 5.34 5.32 5.32 5.31 5.31 20 (a,e) -,1.91 0,1.90 22 (H,OH) 3.20,- 3.20,1.88 3.22 3.20,1.88 3.2023 4.92 4.96 4.96 4.91 4.91 4.92 4.91 24 (H,CH3) -,0.83 -0.84 -,0.84 1.58-0.83 -,0.82 1.62-0.82 -,0.83 25 3.42 3.43 3.43 3.41 3.40 3.40 26 1.21 1.22 1.22 1.21 1.21 27 1.02 2'(H,CH3) 2.43,1.17 2.58,1.17 2.57,- 2.57-1.17 -,1.17 3' 6.61 6.61 1.25,4' 0.32 1.62 1.62 1.62 0.93 5' 0.91,0.88 0.91,0.88 0.91,0.88 Example 2
The individual compounds were screened for their activity against the nematode Ceanorhabditis elegans. The test system involves the suspension of the nematodes in a buffered, antibiotically attentuated
E. colicontaining nutrient medium containing a known concentration of the nematicidal compound. One week after suspension, the test units are examined under the microscope to assess the efficacy of the compound. The method is sensitive to a concentration of 0.01 ppm of ivermectin. The method is an adaption of that described by Simpkin (K G Simpkin and G C Coles, "The use of Caenorhabdites elegans for anthelmintic screening", J. Chem. Biotechnol., 1981, 31, 66-69). Nematode kills of 90% were caused by new compounds 4 and 5 at concentrations of 0.02 and 0.06 ppm rnspectively. In similar tests, the previously described milbemycins alphas 1 and 3 gave similar 90% mortalities at concentrations of 0.05 and 0.01 ppm respectively. Thus it may be concluded that the new milbemcyins 4 and 5 (and, by analogy, the other novel compounds) are of comparable biological activity to those previously described.
Claims (12)
1. A compound of formula (I)
wherein 131 is hydroxy, R2 is hydrogen or methyl, R3 is methyl, and R4 is 2,4-dimethylpentanoyl or 2 4dimethylpent-2-enoyl.
2. A compound according to claim 1 in substantially pure form.
3. A compound according to claim 1 wherein R' is hydroxy, R2 is hydrogen, R3 is methyl and R4 is 2,4 dimethylpent-2-enoyl.
4. A compound according to claim 1 wherein R1 is hydroxy, R2 is hydrogen, R3 is methyl and R4 is 2,4dimethylpentanoyl.
5. A process for preparing a compound of formula (I) as defined in claim 1 which process comprises cultivating a strain of streptomyces and isolating the compound of formula (I) from the fermentation mixture.
6. A process according to claim 4 wherein the Streptomyces strain is NCIB 11876 or a mutant thereof.
7. A process according to claim 6 wherein the Streptomyces strain is NCIB 11876.
8. A pesticidal composition comprising a compound according to claim 1 in combination with a carrier or diluent.
9. A composition according to claim 8 wherein the carrier or diluent is an agriculturally acceptable carrier.
10. A method of controlling or eradicating insects comprising administering to the insect or to an environment thereof a compound of formula (i) as defined in claim 1.
11. A compound substantially as hereinbefore described with reference to the examples.
12. A process for preparing a compound of formula (I), substantially as hereinbefore described with reference to the examples.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB858502925A GB8502925D0 (en) | 1985-02-05 | 1985-02-05 | Macrocyclic lactones |
Publications (3)
Publication Number | Publication Date |
---|---|
GB8600494D0 GB8600494D0 (en) | 1986-02-12 |
GB2170499A true GB2170499A (en) | 1986-08-06 |
GB2170499B GB2170499B (en) | 1988-11-02 |
Family
ID=10573994
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB858502925A Pending GB8502925D0 (en) | 1985-02-05 | 1985-02-05 | Macrocyclic lactones |
GB08600494A Expired GB2170499B (en) | 1985-02-05 | 1986-01-09 | Macrocyclic lactones |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB858502925A Pending GB8502925D0 (en) | 1985-02-05 | 1985-02-05 | Macrocyclic lactones |
Country Status (1)
Country | Link |
---|---|
GB (2) | GB8502925D0 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0317148A2 (en) * | 1987-11-14 | 1989-05-24 | Pfizer Limited | Antiparasitic agents |
US5055596A (en) * | 1987-11-03 | 1991-10-08 | Beecham Group P.L.C. | Derivatives of avermectin and milbemycin |
US5089480A (en) * | 1985-07-27 | 1992-02-18 | Pfizer Inc. | Antiparasitic agents |
US5234831A (en) * | 1987-01-23 | 1993-08-10 | Pfizer Inc | Cultures for production of B avermectins |
US5238848A (en) * | 1987-01-23 | 1993-08-24 | Pfizer Inc | Cultures for production of avermectins |
US5240850A (en) * | 1987-10-23 | 1993-08-31 | Pfizer Inc. | Cultures for production of avermectin aglycones |
US5525506A (en) * | 1987-01-23 | 1996-06-11 | Pfizer Inc. | Process for production of avermectins and cultures therefor |
US5840704A (en) * | 1986-07-16 | 1998-11-24 | Pfizer Inc. | Antiparasitic agents and process for their preparation |
US6103504A (en) * | 1992-03-25 | 2000-08-15 | Pfizer Inc. | Process for production of avermectins and cultures therefor |
US6495591B1 (en) | 1997-10-02 | 2002-12-17 | Essential Therapeutics, Inc. | Fungal efflux pump inhibitors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4144352A (en) * | 1977-12-19 | 1979-03-13 | Merck & Co., Inc. | Milbemycin compounds as anthelmintic agents |
-
1985
- 1985-02-05 GB GB858502925A patent/GB8502925D0/en active Pending
-
1986
- 1986-01-09 GB GB08600494A patent/GB2170499B/en not_active Expired
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4144352A (en) * | 1977-12-19 | 1979-03-13 | Merck & Co., Inc. | Milbemycin compounds as anthelmintic agents |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5451511A (en) * | 1985-07-27 | 1995-09-19 | Pfizer Inc. | Process for the preparation of antiparasitic agents |
US5089480A (en) * | 1985-07-27 | 1992-02-18 | Pfizer Inc. | Antiparasitic agents |
US5840704A (en) * | 1986-07-16 | 1998-11-24 | Pfizer Inc. | Antiparasitic agents and process for their preparation |
US5565359A (en) * | 1987-01-23 | 1996-10-15 | Pfizer Inc. | Cultures for production of B avermectins |
US5525506A (en) * | 1987-01-23 | 1996-06-11 | Pfizer Inc. | Process for production of avermectins and cultures therefor |
US5234831A (en) * | 1987-01-23 | 1993-08-10 | Pfizer Inc | Cultures for production of B avermectins |
US5238848A (en) * | 1987-01-23 | 1993-08-24 | Pfizer Inc | Cultures for production of avermectins |
US5583015A (en) * | 1987-01-23 | 1996-12-10 | Pfizer Inc. | Process for production of avermectins |
US5576199A (en) * | 1987-01-23 | 1996-11-19 | Pfizer Inc. | Process for production of B avermectins |
US5240850A (en) * | 1987-10-23 | 1993-08-31 | Pfizer Inc. | Cultures for production of avermectin aglycones |
US5055596A (en) * | 1987-11-03 | 1991-10-08 | Beecham Group P.L.C. | Derivatives of avermectin and milbemycin |
US5702924A (en) * | 1987-11-14 | 1997-12-30 | Pfizer Inc. | Process for preparing antiparasitic agents |
JPH01160983A (en) * | 1987-11-14 | 1989-06-23 | Pfizer Ltd | Anti-parasitic agent |
EP0317148A3 (en) * | 1987-11-14 | 1990-11-28 | Pfizer Limited | Antiparasitic agents |
JP2854869B2 (en) * | 1987-11-14 | 1999-02-10 | ファイザー・リミテッド | Antiparasitic agent |
US6362168B1 (en) | 1987-11-14 | 2002-03-26 | Pfizer Inc. | Antiparasitic agents |
EP0317148A2 (en) * | 1987-11-14 | 1989-05-24 | Pfizer Limited | Antiparasitic agents |
US6103504A (en) * | 1992-03-25 | 2000-08-15 | Pfizer Inc. | Process for production of avermectins and cultures therefor |
US6495591B1 (en) | 1997-10-02 | 2002-12-17 | Essential Therapeutics, Inc. | Fungal efflux pump inhibitors |
Also Published As
Publication number | Publication date |
---|---|
GB8502925D0 (en) | 1985-03-06 |
GB2170499B (en) | 1988-11-02 |
GB8600494D0 (en) | 1986-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Takiguchi et al. | Milbemycins, a new family of macrolide antibiotics: fermentation, isolation and physico-chemical properties | |
EP0170006B1 (en) | Method and compositions for helmintic, arthropod ectoparasitic and acaridal infections with novel agents | |
Krause et al. | Microbial transformation of the herbicide metolachlor by a soil actinomycete | |
Braekman et al. | Jaspamide from the marine sponge Jaspis johnstoni | |
Abbott et al. | Microbial transformation of A23187, a divalent cation ionophore antibiotic | |
EP0254583B1 (en) | Parasiticidal milbemycin derivatives, a process for their production, and compositions containing the same | |
CS207397B2 (en) | Method of preparation of the new anthelmintic compounds | |
GB2170499A (en) | Pesticidal and anthelmintic milbemycins | |
DE68928606T2 (en) | Anti-parasitic macrolide antibiotics | |
SU1036251A3 (en) | Process for preparing antibiotic c=15003 p-3 | |
JPH01160983A (en) | Anti-parasitic agent | |
US4869901A (en) | Method and compositions for helmintic, arthropod ectoparasitic and acaridal infections with novel agents | |
CN111303184B (en) | Macrolide compound and preparation method and application thereof | |
US5439934A (en) | Method and compositions for helmintic, arthropod ectoparasitic and acaridal infections with novel agents | |
DE3234203C2 (en) | ||
EP0298423A2 (en) | Antibiotic KSB-1939 compounds and production process thereof as well as pesticidal agents containing same | |
CN112961168B (en) | Macrolide new compound and preparation method and application thereof | |
US5158960A (en) | 10'-Desmethoxystreptonigrin | |
IE912199A1 (en) | Antiparasitic agents | |
US5198464A (en) | Method and compositions for helmintic, arthropod ectoparasitic and acaridal infections with novel agents | |
EP1118617B1 (en) | Compounds with an antioxidant acitivity, compositions useful as food integrators containing them and process for their preparation | |
US4298692A (en) | Fermentation process for producing a rifamycin derivative | |
DE2746209C2 (en) | ||
DK144658B (en) | PROCEDURE FOR THE PREPARATION OF ANTIBIOTIC C-15003 P-4 | |
EP0050964B1 (en) | Macrocyclic lactones, their production and parasiticidal uses, compositions containing them, and a biological culture suitable for producing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
732E | Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977) | ||
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19940109 |